In vivo safety, toxicity, biocompatibility and anti-tumour efficacy of bioinspired silver and selenium nanoparticles

被引:13
|
作者
Mittal, Amit Kumar [1 ,2 ]
Banerjee, Uttam Chand [1 ]
机构
[1] Natl Inst Pharmaceut Educ & Res, Dept Pharmaceut Technol Biotechnol, Block H,Sect 67, Sas Nagar 160062, Punjab, India
[2] Amity Univ, Amity Inst Indian Syst Med AIISM, Noida 201313, Uttar Pradesh, India
来源
关键词
Silver nanoparticles; Nano-toxicity; Anti-tumour; Biological synthesis; Histopathology; DNA fragmentation; BIOMEDICAL APPLICATIONS; METAL NANOPARTICLES; GREEN SYNTHESIS; BIOSYNTHESIS; ANTIOXIDANT; ANTICANCER; AGENT; VITRO;
D O I
10.1016/j.mtcomm.2020.102001
中图分类号
T [工业技术];
学科分类号
08 ;
摘要
The present work was carried out to know the in vivo evaluation of safety, toxicity and efficacy of the various biosynthesized inorganic nanoparticles of various sizes and shapes. Several kinds of silver and selenium inorganic nanomaterials were synthesized using plant extracts and phytochemicals. The size and shape of these bioinspired nanomaterials were characterized using various spectroscopic and microscopic techniques. All the synthesized nanomaterials were found to be less than 35 nm in size and having hexagonal and spherical shapes resoluted via electron microscopy analysis. Biocompatibilities of the all biosynthesized nanoparticles were evaluated using hemolysis assay exhibiting lower hemolytic effect (less than 10 %) and LAL assays showing free of endotoxin. Safety and toxicities of synthesized nanocomposites were evaluated on Swiss mice using various bio-assays including haematological, biochemical, histopathological and DNA fragmentation assays. The biosynthesized nanomaterials did not produce significant level of toxicity in terms of haematological, biochemical, histological and DNA damage parameters. Following the surprising results with safety and negligible toxicity of the synthesized nanoparticles, In vivo anti-tumour potential were proposed and evaluated in DMBA induced breast cancer model of SD female rats. The results of the study presented the significant decrease in the tumour volume after administration of nanoparticles. Conclusively, the bio-inspired nanocomposite synthesized by biological route did not produce significant level of toxic effect with higher level of therapeutic effectiveness. These synthesized biological materials can be used for the management of various types of life threatening emergencies.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Pharmacokinetics, Biodistribution, Acute Toxicity and In Vivo Anti-tumour Efficacy of Paclitaxel Solid Dispersion
    Liu, Xiangrui
    Sun, Jiabei
    Chen, Xiaomei
    Wang, Shudong
    Zhang, Xuan
    Zhang, Qiang
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2010, 62 (10) : 1234 - 1235
  • [2] A Reflection on the Mechanism of the Role of Nanoparticles in Increasing the Efficacy of Anti-tumour Properties of Docetaxel
    Manivannan, Sivakami
    Nagaraj, Saraswathi
    Narayan, Shoba
    CURRENT PATHOBIOLOGY REPORTS, 2021, 9 (03) : 79 - 91
  • [3] Toxicity and anti-tumour efficacy of oxaliplatin on Glasgow Osteosarcoma in mice:: a mathematical model.
    Clairambault, J
    Claude, D
    Filipski, E
    Granda, T
    Lévi, F
    PATHOLOGIE BIOLOGIE, 2003, 51 (04): : 212 - 215
  • [4] In vivo and in vitro anti-tumour response of selenium-protein polysaccharide extracted from rich selenium Agaricus blazei
    Chen, Che
    Zhang, Yingmei
    Li, Yanchao
    Chu, Huiyuan
    Xi, Yaming
    FOOD AND AGRICULTURAL IMMUNOLOGY, 2007, 18 (02) : 139 - 149
  • [5] Enhancing anti-tumour efficacy with immunotherapy combinations
    Meric-Bernstam, Funda
    Larkin, James
    Tabernero, Josep
    Bonini, Chiara
    LANCET, 2021, 397 (10278): : 1010 - 1022
  • [6] Enhancing NK cell anti-tumour efficacy
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2022, 21 (6) : 416 - 416
  • [7] TOXICITY AND ANTI-TUMOUR ACTION OF SOME ALKYLATING SULPHONAMIDES
    HAWKINS, R
    OWEN, LN
    DANIELLI, JF
    JOURNAL OF THEORETICAL BIOLOGY, 1963, 5 (02) : 236 - &
  • [8] Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor
    Ben-Horin, S.
    Ungar, B.
    Kopylov, U.
    Lahat, A.
    Yavzori, M.
    Fudim, E.
    Picard, O.
    Peled, Y.
    Eliakim, R.
    Del Tedesco, E.
    Paul, S.
    Roblin, X.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (08) : 1117 - 1125
  • [9] Pharmaceutical strategies in improving anti-tumour efficacy and safety of intraperitoneal therapy for peritoneal metastasis
    Wang, Puxiu
    Qu, Xiujuan
    Che, Xiaofang
    Luo, Qiuhua
    Tang, Xing
    Liu, Yunpeng
    EXPERT OPINION ON DRUG DELIVERY, 2021, 18 (09) : 1193 - 1210
  • [10] In vivo anti-tumour activity of novel Quinazoline derivatives
    Alapati, V.
    Noolvi, M. N.
    Manjula, S. N.
    Pallavi, K. J.
    Patel, H. M.
    Tippeswamy, B. S.
    Satyanarayana, S. V.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2012, 16 (13) : 1753 - 1764